Evolent Health, Inc. (EVH) — Financial statements
Income statement, balance sheet, and cash flow for Evolent Health, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,876↓26.6% | 2,555↑30.1% | 1,964↑45.3% | 1,352↑48.9% | 908 | |
| Cost of Revenue | 1,592↓27.2% | 2,187↑45.5% | 1,503↑45.2% | 1,035↑57.5% | 658 | |
| Gross Profit | 284↓22.7% | 367↓20.2% | 460↑45.4% | 317↑26.4% | 250 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00↓100.0% | 27 | 0.00 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 219 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 288↑9.7% | 263↓26.5% | 358↑33.0% | 269↑22.7% | 219 | |
| Other Expenses | 0.00↓100.0% | 145↓16.6% | 174↑941.0% | 17↓77.3% | 73 | |
| Operating Expenses | 288↓29.3% | 408↓23.3% | 532↑69.9% | 313↑6.9% | 293 | |
| Total Costs & Expenses | 1,881↓27.5% | 2,595↑27.5% | 2,035↑50.9% | 1,348↑41.9% | 950 | |
| Operating Results | ||||||
| Operating Income | -4↑89.0% | -40↑43.1% | -71↓2055.3% | 4↑108.6% | -42 | |
| Depreciation & Amortization | 116↓5.9% | 123↓0.2% | 123↑36.7% | 90↑50.3% | 60 | |
| EBITDA | 111↑31.3% | 85↑442.4% | -25↓156.7% | 44↓21.4% | 56 | |
| EBIT | -4↑88.4% | -38↑74.1% | -148↓218.7% | -47↓962.7% | -4 | |
| Interest & Other Income | ||||||
| Net Interest Income | -53↓177.8% | -19↑60.8% | -49↓244.6% | -14↑43.2% | -25 | |
| Interest Income | 4↓24.4% | 6↑5.5% | 5↑283.9% | 1↑236.4% | 0.41 | |
| Interest Expense | 57↑132.5% | 25↓54.4% | 54↑248.1% | 16↓38.8% | 25 | |
| Non-Operating Income | 0.00↑100.0% | -2↓102.8% | 77↑53.5% | 50↑231.8% | -38 | |
| Other Income / Expenses | -530↓2251.1% | -23↑82.8% | -131↓99.6% | -66↓621.2% | 13 | |
| Income Before Tax | -535↓748.1% | -63↑68.9% | -202↓226.1% | -62↓108.3% | -30 | |
| Income Tax Expense | -0.13↑91.1% | -1↑98.4% | -89↓106.0% | -43↓9080.5% | 0.48 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -535↓767.4% | -62↑45.5% | -113↓504.5% | -19↑38.2% | -30 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00↑100.0% | -0.46↑93.7% | -7 | |
| Net Income | -535↓767.4% | -62↑45.5% | -113↓489.9% | -19↑49.0% | -38 | |
| Bottom-Line Net Income | -579↓520.0% | -93↑34.3% | -142↓660.7% | -19↑50.3% | -38 | |
| EPS (Basic) | -5.07↓525.9% | -0.81↑36.7% | -1.28↓540.0% | -0.20↑44.4% | -0.36 | |
| EPS (Diluted) | -5.07↓525.9% | -0.81↑36.7% | -1.28↓540.0% | -0.20↑44.4% | -0.36 | |
| Weighted Average Shares | 114↓0.4% | 115↑3.1% | 111↑18.7% | 94↑8.9% | 86 | |
| Weighted Average Diluted Shares | 114↓0.4% | 115↑3.1% | 111↑18.7% | 94↑8.9% | 86 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.